Literature DB >> 23532441

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Daniel E Furst1, Edward Clark Keystone, Alexander K So, Jürgen Braun, Ferry C Breedveld, Gerd R Burmester, Fabrizio De Benedetti, Thomas Dörner, Paul Emery, Roy Fleischmann, Allan Gibofsky, J R Kalden, Arthur Kavanaugh, Bruce Kirkham, Philip Mease, A Rubbert-Roth, Joachim Sieper, Nora G Singer, Josef S Smolen, Piet L C M Van Riel, Michael H Weisman, Kevin L Winthrop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23532441     DOI： 10.1136/annrheumdis-2013-203348

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  33 in total

Review 1.  Biological therapy and dentistry: a review paper.

Authors:  Lida Radfar; Roshanak E Ahmadabadi; Farah Masood; R Hal Scofield
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2015-07-31

2.  Premedication prevents infusion reactions and improves retention rate during infliximab treatment.

Authors:  Francesca Bartoli; Cosimo Bruni; Laura Cometi; Jelena Blagojevic; Ginevra Fiori; Lorenzo Tofani; Felice Galluccio; Daniel E Furst; Marco Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2016-07-19       Impact factor: 2.980

3.  Immunogenicity, the elephant in the room. Comment on "Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNFα biologics in rheumatic diseases".

Authors:  John Pixley
Journal:  Clin Rheumatol       Date:  2013-08-24       Impact factor: 2.980

Review 4.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

5.  [Modern disease-modifying antirheumatic drugs].

Authors:  U Müller-Ladner; K Richter; I H Tarner
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

6.  Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.

Authors:  Xerxes Pundole; Natalia V Zamora; Harish Siddhanamatha; Heather Lin; Jean Tayar; Leung Cheuk Hong; Liang Li; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2019-12-18       Impact factor: 2.980

Review 7.  [What is ascertained in the therapy of axial spondyloarthritis?].

Authors:  J Braun; X Baraliakos; F Heldmann; U Kiltz
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

8.  Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation.

Authors:  Andrew M Harrison; Nassir M Thalji; Alexandra J Greenberg; Carmen J Tapia; Anthony J Windebank
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

Review 9.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Authors:  Glen S Hazlewood; Cheryl Barnabe; George Tomlinson; Deborah Marshall; Daniel J A Devoe; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

Review 10.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.